Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649

被引：0
|
作者：
Moehler, M. [1 ]
Elimova, E. [2 ]
Blum, S., I [3 ]
Xiao, H. [3 ]
Davenport, E. [4 ]
Wang, J. [4 ]
Hunter, S. [4 ]
Li, M. [3 ]
Kondo, K. [3 ]
Wyrwicz, L. [5 ]
机构：
[1] Johannes Gutenberg Univ Clin, Mainz, Germany
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] RTI Hlth Solut, Res Triangle Pk, NC USA
[5] Narodowy Inst Onkol, Klin Onkol & Radioterapii, Warsaw, Poland
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ep150
引用
下载
收藏
页码：214 / 215
页数：2
相关论文
共 50 条
  • [31] First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: a cost-effectiveness analysis
    Cao, Xueqiong
    Zhang, Mingming
    Li, Na
    Zheng, Bin
    Liu, Maobai
    Song, Xiaobing
    Cai, Hongfu
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [32] DIRECT AND INDIRECT COSTS ASSOCIATED WITH UNRESECTABLE ADVANCED OR METASTATIC (ADV/MET) GASTRIC CANCER (GC), GASTROESOPHAGEAL JUNCTION CANCER (GEJC) AND ESOPHAGEAL ADENOCARCINOMA (EAC) FOR PATIENTS AND THEIR CAREGIVERS
    Hall, J.
    Khela, K.
    Bertwistle, D.
    Xiao, H.
    VALUE IN HEALTH, 2020, 23 : S482 - S483
  • [33] Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma
    Daniel Lin
    Hiep Nguyen
    Ruchit Shah
    Yao Qiao
    John Hartman
    Ryan Sugarman
    Gastric Cancer, 2023, 26 : 415 - 424
  • [34] Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma
    Lin, Daniel
    Nguyen, Hiep
    Shah, Ruchit
    Qiao, Yao
    Hartman, John
    Sugarman, Ryan
    GASTRIC CANCER, 2023, 26 (03) : 415 - 424
  • [35] First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
    Janjigian, Yelena Y.
    Ajani, Jaffer A.
    Moehler, Markus
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Wyrwicz, Lucjan
    Yamaguchi, Kensei
    Cleary, James M.
    Elimova, Elena
    Karamouzis, Michalis
    Bruges, Ricardo
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshi
    Tehfe, Mustapha
    Zander, Thomas
    Kowalyszyn, Ruben
    Pazo-Cid, Roberto
    Schenker, Michael
    Feeny, Kynan
    Wang, Rui
    Lei, Ming
    Chen, Clara
    Nathani, Raheel
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17) : 2012 - 2020
  • [36] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study.
    Cruz-Correa, Marcia
    Xu, Rui-Hua
    Moehler, Markus H.
    Oh, Do-Youn
    Kato, Ken
    Spigel, David R.
    Arkenau, Hendrik-Tobias
    Tabernero, Josep
    Zimina, Anastasia V.
    Bai, Yuxian
    Shi, Jianhua
    Lee, Keun-Wook
    Hirano, Hidekazu
    Wyrwicz, Lucjan S.
    Pazo Cid, Roberto
    Xu, Hui
    Sheng, Tao
    Barnes, Gisoo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 290 - 290
  • [37] Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer
    Mansoor, Wasat
    Joo, Seongjung
    Norquist, Josephine M.
    Kato, Ken
    Sun, Jong-Mu
    Shah, Manish A.
    Enzinger, Peter
    Adenis, Antoine
    Doi, Toshihiko
    Kojima, Takashi
    Metges, Jean-Philippe
    Li, Zhigang
    Kim, Sung-Bae
    Cho, Byoung Chol
    Sunpaweravong, Patrapim
    Maqueda, Maria Alsina
    Goekkurt, Eray
    Suryawanshi, Shailaja
    Shah, Sukrut
    Shen, Lin
    ONCOLOGIST, 2024,
  • [38] Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC)
    Chen, Zhendong
    Bai, Yuxian
    Zhang, Tao
    Ying, Jieer
    Lin, Xiaoyan
    Yang, Liu
    Wang, Jun
    Zhang, Juan
    Yu, Fan
    Fei, Cong
    Huang, Ruiqi
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [39] Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
    Jiang, Yuan
    Li, Yue
    Wang, Larry X. W.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (02) : 499 - 506
  • [40] Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
    Yuan Jiang
    Yue Li
    Larry X. W. Wang
    International Journal of Clinical Pharmacy, 2022, 44 : 499 - 506
12345